Pharmaceutical companies, such as Emmaus Medical, Cosmo Pharmaceuticals, and others, are actively working toward the development of potential therapies in order to fulfill the unmet medical needs of the currently used therapeutics. Of the emerging therapies, the most anticipated product to get launched are Aemcolo, Endari, and others. The pipeline for Diverticulitis- though not very vast – provides an opportunity for other key players to hold a great share of the market
DelveInsight’s “Diverticulosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Diverticulosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Diverticulosis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Diverticulosis: An Overview
Diverticulitis is a digestive condition that affects the large intestine (bowel). Diverticulosis is a condition that occurs when small pouches, or sacs, form and push outward through weak spots in the wall of the colon. Diverticulitis occurs when one has diverticulosis and one or a few of the pouches in the wall of the colon become inflamed.
In diverticulitis, the inflamed pouches most often cause pain in the lower left side of the abdomen. The pain is usually severe and comes on suddenly, but it can also be mild and worsen over several days. The intensity of the pain can change over time. The goal of treating diverticulosis is to prevent the pouches from causing symptoms or problems.
Diverticulosis Market Key Facts
-
According to the “National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center,” about 70,000 people are hospitalized for diverticular bleeding each year.
-
Experts used to think that 10 to 25 % of people with diverticulosis would develop diverticulitis. However, newer research suggests that the percentage who develop diverticulitis may be much lower—less than 5 percent.
-
According to the study titled “Epidemiology, Pathophysiology, and Treatment of Diverticulitis” conducted by Lisa L. Strate et al. (2019), Diverticulitis is a prevalent gastrointestinal disorder that is associated with significant morbidity and health care costs. Approximately 20% of patients with incident diverticulitis have at least 1 recurrence. The lifetime risk of diverticulitis in a person with diverticulosis was reported to range from 10% to 25%.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Diverticulosis market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Diverticulosis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Diverticulosis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Diverticulosis Epidemiology, Segmented as –
-
Total Prevalent Cases of Diverticulitis (2019–2032)
-
Gender-specific Prevalent Cases of Diverticulitis (2019–2032)
-
Diagnosed and Treatable Cases of Diverticulitis (2019–2032)
-
Age-specific Prevalent Cases of Diverticulitis (2019–2032)
Diverticulosis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Diverticulosis market or expected to be launched during the study period. The analysis covers the Diverticulosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Diverticulosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Diverticulosis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/diverticulitis-market
Diverticulosis Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Diverticulitis. Currently, Salix Pharmaceuticals is leading the therapeutics market with its Diverticulitis drug candidates in the most advanced stage of clinical development.
Some of the Key Players in the Diverticulosis Therapeutics Market Include:
-
Salix Pharmaceuticals
-
Emmaus Medical
-
Cosmo Pharmaceuticals
And Many Others
Diverticulitis Emerging and Marketed Drugs Covered in the Report Include:
-
Rifamycin: Salix Pharmaceuticals
-
Aemcolo: Cosmo Pharmaceuticals
-
Endari: Emmaus Medical
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/diverticulitis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Diverticulosis Competitive Intelligence Analysis
4. Diverticulosis Market Overview at a Glance
5. Diverticulosis Disease Background and Overview
6. Diverticulosis Patient Journey
7. Diverticulosis Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Diverticulosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Diverticulosis Unmet Needs
10. Key Endpoints of Diverticulosis Treatment
11. Diverticulosis Marketed Products
12. Diverticulosis Emerging Drugs and Latest Therapeutic Advances
13. Diverticulosis Seven Major Market Analysis
14. Attribute Analysis
15. Diverticulosis Market Outlook (In US, EU5, and Japan)
16. Diverticulosis Access and Reimbursement Overview
17. KOL Views on the Diverticulosis Market
18. Diverticulosis Market Drivers
19. Diverticulosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/diverticulitis-market
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/